ノボ・ノルディスク
時価総額
$125.9B
世界順位
#131
過去最高値
$315.6B
2023-12-31
総成長率
+0%
2026年以降
Market Cap Context
- Larger than 64% of the 367 companies we track (globally).
- Equivalent to 27.2% of Denmark's GDP (2025 data).
- Just above: #130 キーエンス ($127.4B)
- Just below: #132 Bristol-Myers Squibb Company ($125.6B)
- Best year: 2007 (+189%). Worst year: 2008 (-59%).
ノボ・ノルディスク Financial Breakdown (FY 2025)
Source: Yahoo Finance — NOVO-B.CO annual filings (2025) (converted from DKK at 6.85) →$45.1B revenue · $18.6B operating income · $15.0B net income
- ●Operating margin: 41.3% on $45.1B in revenue.
- ●R&D is 16.8% of revenue ($7.6B).
- ●Net income margin: 33.1% — $15.0B in profit.
- ●Free cash flow: $4.2B (9.4% of revenue).
Cost / Operating Expenses
Total operating expenses $26.5B
Total
$26.4B
Capital Expenditures
$13.2B
This fiscal year (near-total AI infrastructure buildout)
Free Cash Flow
$4.2B
Trailing twelve months
Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.
ノボ・ノルディスクについて
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.
ノボ・ノルディスクの時価総額推移 (2026–2026)
ノボ・ノルディスク vs Sector Peers by Market Cap
ノボ・ノルディスクを比較
順位の推移
| 年 | 時価総額 | 順位 | 前年比 |
|---|---|---|---|
| 2026 | $125.9B | #131(↓24) | -17.7% |
| 2025 | $152.9B | #107(↓78) | -46.4% |
| 2024 | $285.3B | #29(↓5) | -9.6% |
| 2023 | $315.6B | #24(↑11) | +50.7% |
| 2022 | $209.4B | #35(↑24) | +29.5% |
| 2021 | $161.6B | #59(↑30) | +75.6% |
| 2020 | $92.0B | #89(↓8) | +12.8% |
| 2019 | $81.6B | #81(↑2) | +32.9% |
| 2018 | $61.4B | #83(↓11) | -8.6% |
| 2017 | $67.2B | #72(↑20) | +35.4% |
| 2016 | $49.6B | #92(↓43) | -34.5% |
| 2015 | $75.8B | #49(↑27) | +55.9% |
| 2014 | $48.6B | #76(↑16) | +33.4% |
| 2013 | $36.5B | #92(↓18) | +10.5% |
| 2012 | $33.0B | #74(↑13) | +41.3% |
| 2011 | $23.3B | #87(↓40) | -46.7% |
| 2010 | $43.8B | #47(↑33) | +92.7% |
| 2009 | $22.7B | #80(↑65) | +150.6% |
| 2008 | $9.1B | #145(↓47) | -59.0% |
| 2007 | $22.1B | #98(↑102) | +189.1% |
| 2006 | $7.7B | #200(↑3) | +34.9% |
| 2005 | $5.7B | #203(↓67) | -39.8% |
| 2004 | $9.4B | #136(↓7) | +26.3% |
| 2003 | $7.5B | #129(↓8) | +19.5% |
| 2002 | $6.2B | #121(↓29) | -39.5% |
| 2001 | $10.3B | #92 |
その他のヘルスケア企業
よくある質問
What is Novo Nordisk A/S's market cap?
Novo Nordisk A/S (NOVO-B.CO) has a market capitalization of $125.9B, making it the #131 largest company in the world by market cap.
What was Novo Nordisk A/S's highest market cap?
Novo Nordisk A/S's all-time high market cap was $315.6B, reached in 2023-12-31. Its highest rank was #24 in 2023.
What sector is Novo Nordisk A/S in?
Novo Nordisk A/S is in the Healthcare sector, specifically the Drug Manufacturers - General industry. It is based in Denmark.
How has Novo Nordisk A/S's market cap changed over time?
Novo Nordisk A/S has been tracked since 2026. Its market cap has grown by 0% from $125.9B in 2026 to $125.9B today.